RxDoctor Payments Data

Kris Howard, MD

Procedural Dermatology · Odessa, TXNPI 1740283019

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,576 of the $3,036 with a category attached, or 84.9%. It is spread thinly across 24 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $716 and has fallen 55.4% since, to $320 in 2025.

$3,036in general payments, 2019–2025

Across 180 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$547
  • Mayne Pharma Commercial LLC$439
  • Lilly USA, LLC$438
  • AbbVie$231
  • Novartis$225
  • E.r. Squibb & Sons, L.L.C.$179
  • plus $977 from 18 others

What the payments were for

  • Food & beverage$2,57685%
  • Education$46015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,036 in reported general payments places this provider in the 55th percentile of 25 procedural dermatology providers in Texas.

See all procedural dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$347,296
Medicare patients
1,062
Services billed
4,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Unoready PenSecukinumab16$212,481
Taltz AutoinjectorIxekizumab13$88,796
Humira(Cf) PenAdalimumab13$81,806
Taltz SyringeIxekizumab12$78,614
Dupixent PenDupilumab13$46,924
Fluorouracil80$5,797
Doxycycline Ir-DrDoxycycline Monohydrate12$5,711
Clobetasol Propionate100$4,602
Fluocinonide-EFluocinonide/Emollient Base27$1,808
Metronidazole23$1,715
Triamcinolone Acetonide110$1,142
Doxycycline Hyclate74$1,005
ValacyclovirValacyclovir Hcl33$994
Clindamycin Phosphate18$969
Hydroxychloroquine Sulfate24$945

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →